IQVIA

Market Reflection Report

DEC 2022

10th Jan 2023

© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 IPM Overview
SSA
TSA
Growth %%

80 60
60 2019-20
40
40 2020-21
20
20 2021-22
0 0
-20 -20
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

TSA IPM Trends (Value Rs. 193,838 Crs) – MAT Dec'22 SSA IPM Trends (Value Rs. 164,242 Crs) – MAT Dec'22

+13%
7% +12%
7%
MAT
193,838 MAT
181,968 Month 164,242
154,205 Month

153,943
147,112 131,872
124,108

13,821 15,168 17,097 11,656 12,845 14,440

12,324 10,348

2019 2020 2021 2022 2019 2020 2021 2022

• IPM- TSA valued at Rs. 193,838 Cr with growth of 7% as of MAT Dec’22 and Rs 17,097 Cr for Dec’22 month with growth of 13%
• SSA valued at Rs. 164,242 Cr with growth of 7% as of MAT Dec’22 and Rs 14,440 Cr for Dec’22 month with growth of 12%

IQVIA TSA & SSA Dataset Dec’22 1

 Anti-Infectives followed by Respiratory posted highest growth
amongst top 10 therapies for the month of Dec’22
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)
21 15
14 9 10 13
4 5 6 3
IPM 17,097 -6 IPM
-9
10 8 10 11 12 15 12
5 8 7
CARDIAC 2,131 -4 -3 Cardiac
50
4 20 11 12 15 22
ANTI-INFECTIVES 1,930 -6 1 -1 AI
86 -29 -28
16 11 18 16 9 2 16 21
-24 -30 -8 Resp
RESPIRATORY 1,781
15 21 15
9 8 12 13 10 12 11
GASTRO 1,663 3 2 Gastro
9 8 8 9 9
7 7 6
ANTI DIABETIC 1,534 1 3 1 5 ADB
2
28 25 14 16 16
4 8 -2 11 13 9 Pain
PAIN 1,330
16 14
6 8 5 7 7 10
2 1 VMN
VMN 1,277 -13 -14
13
6 5 5 7 6
DERMA 1,180 2 2 3 2 4
-3 Derma
15 14 14 12
9 9 9 9 11 10
NEURO 1,035 4 5 Neuro
20 30 22 20
9 3 10 10 14 15 8 14
Gynae
GYNAEC. 830
Jan Feb Feb Apr May Jun Jul Aug Sep Oct Nov Dec

Therapy sorted on Month

IQVIA TSA Dataset Dec’22
2
 Top Companies #1-10 Market Share Trend
9

Val Dec’22 MS Dec’22

8 SUN* 1325 7.75%
ABBOTT* 1058 6.19%

7 CIPLA 982 5.74%

(MANKIND) 755 4.42%
(ALKEM*) 670 3.92%
6
LUPIN 603 3.53%
INTAS* 591 3.45%
5
TORRENT 584 3.42%
(MACLEODS) 574 3.36%
4 (DRL) 508 2.97%

2
Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22

• Sun*, Abbott*, Cipla, Lupin, Intas* & Torrent have shown improvement in MS for Dec’22 as compared to Nov’22
• Mankind, Alkem*, Macleods & DRL reflected slight dip in MS for Dec’22 as compared to Nov’22

IQVIA TSA Dataset Dec'22 3

 Top Companies #1-10
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

SUN* 1,325 12 99 SUN* 1,126 11 98

ABBOTT* 1,058 11 98 ABBOTT* 900 11 99
CIPLA 982 18 104 CIPLA 825 17 104
MANKIND 755 24 110 MANKIND 679 23 110
Month

Month
ALKEM* 670 22 108 ALKEM* 578 19 106
LUPIN 603 9 96 LUPIN 515 7 95
INTAS* 591 15 102 TORRENT 512 14 101

TORRENT 584 15 102 MACLEODS 510 19 105

MACLEODS 574 19 106 INTAS* 482 13 101

4 92 DRL 437 3 91
DRL 508

SUN* 14,927 11 104 SUN* 12,775 10 104

ABBOTT* 11,996 9 102 ABBOTT* 10,246 9 102
CIPLA 10,182 5 98 CIPLA 8,562 7 101
MANKIND 8,390 8 101 MANKIND 7,553 8 101
MAT

104

MAT
ALKEM* 7,807 11 104 ALKEM* 6,797 11
LUPIN 6,788 6 99 LUPIN 5,839 5 98
INTAS* 6,593 14 107 TORRENT 5,790 11 105
TORRENT 6,572 12 105 MACLEODS 5,587 9 102
MACLEODS 6,298 10 103 INTAS* 5,400 13 106
DRL 5,747 3 96 ARISTO* 5,037 4 98

• TSA & SSA : Mankind has posted highest growth on Month level followed by Alkem* and for MAT level Intas* has posted highest growth followed by Alkem*

IQVIA TSA & SSA Dataset Dec'22 4

 Top Companies #11-20 Market Share Trend
3.2

3.0
Val Dec’22 MS Dec’22
2.8 (ZYDUS*) 489 2.86%
2.6 (ARISTO*) 468 2.73%
2.4 (GSK*) 442 2.58%
GLENMARK 382 2.24%
2.2
(EMCURE*) 341 1.99%
2.0
USV 327 1.92%
1.8 IPCA 320 1.87%
1.6 (PFIZER*) 288 1.68%

1.4 (MICRO*) 285 1.67%

ALEMBIC 274 1.60%
1.2

1.0

0.8

0.6
Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22

• Glenmark, USV, IPCA & Alembic have shown improvement in MS for Dec’22 as compared to Nov’22
• Zydus*, Aristo*, GSK*, Emcure*, Pfizer* & Micro* reflected dip in MS for Dec’22 as compared to Nov’22
.

IQVIA TSA & SSA Dataset Dec'22 5

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

10 98 ARISTO* 423 15 102

ZYDUS* 489
15 102 ZYDUS* 396 10 98
ARISTO* 468
12 100 GSK* 359 16 103
GSK* 442
15 102 GLENMARK 336 16 103
GLENMARK 382
Month

Month
12 99 USV 291 11 99
EMCURE* 341
10 97 EMCURE* 285 14 101
USV 327
17 103 IPCA 271 15 102
IPCA 320
5 93 ALEMBIC 246 17 104
PFIZER* 288
13 100 MICRO * 245 18 105
MICRO * 285
18 105 PFIZER* 223 9 97
ALEMBIC 274

ZYDUS* 5,629 6 100 DRL 4,949 2 96

ARISTO* 5,557 4 98 ZYDUS* 4,588 6 100
GSK* 4,967 6 99 GSK* 4,018 6 100
GLENMARK 4,106 -6 88 GLENMARK 3,605 -5 89
MAT

96 103

MAT
EMCURE* 3,979 2 USV 3,352 10
USV 3,754 8 102 EMCURE* 3,277 6 100
IPCA 3,556 13 106 IPCA 3,057 12 105
MICRO * 3,281 6 100 MICRO * 2,785 7 101
PFIZER* 3,257 -5 89 ALEMBIC 2,639 7 101
SANOFI* 3,115 -1 93 PFIZER* 2,526 -4 90

• TSA: Alembic has posted the highest growth followed by IPCA on month level, and for MAT, IPCA followed by Alembic posted highest growth

• SSA: Micro* posted highest growth for the month followed by Alembic, whereas for MAT, IPCA followed by USV posted highest growth

IQVIA TSA & SSA Dataset Dec'22 6

 Top Companies #21-30 Market Share Trend
1.8
Val Dec’22 MS Dec’22
1.7
(SANOFI*) 256 1.50%
1.6 JB PHARMA* 169 0.99%
1.5 ERIS* 166 0.97%

1.4 HIMALAYA 143 0.84%

(FDC) 142 0.83%
1.3
AJANTA 133 0.78%
1.2
(FRANCO) 124 0.72%
1.1 118 0.69%
(CADILA)
1.0 LA RENON 108 0.63%

0.9 INDOCO* 106 0.62%

0.8

0.7

0.6

0.5
Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22

• JB Pharma*, Eris*, Himalaya, Ajanta & La Renon have shown improvement in MS for Dec’22 as compared to Nov’22
• Indoco* has maintained MS in the month of Dec’22
• Sanofi*, FDC, Franco & Cadila reflected dip in MS for Dec’22 as compared to Nov’22

IQVIA TSA & SSA Dataset Dec'22 7

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

87 SANOFI* 196 -3 87
SANOFI* 256 -1
28
114 JB PHARMA* 146 26 112
JB PHARMA* 169
7 95 ERIS* 144 7 95
ERIS* 166
7 95 FDC 128 20 107
HIMALAYA 143
Month

Month
20 107 HIMALAYA 128 6 94
FDC 142
17 104 AJANTA 117 16 104
AJANTA 133
19 106 FRANCO 115 19 106
FRANCO 124
3 92 CADILA 97 3 92
CADILA 118
20 107 INDOCO* 96 7 95
LA RENON 108
7 95 BLUE CROSS 91 8 96
INDOCO* 106

ALEMBIC 2,937 9 102 SANOFI* 2,396 0 94

FDC 1,986 12 105 FDC 1,825 12 105
ERIS* 1,889 7 101 ERIS* 1,634 6 100
JB PHARMA* 1,842 19 112 JB PHARMA* 1,621 19 112
MAT

97 3 96

MAT
HIMALAYA 1,628 3 HIMALAYA 1,461
CADILA 1,468 2 96 FRANCO 1,290 -1 93
AJANTA 1,436 15 108 AJANTA 1,274 13 106
FRANCO 1,390 0 94 CADILA 1,200 0 94
INDOCO* 1,253 4 98 INDOCO* 1,138 4 97
LA RENON 1,173 29 121 BLUE CROSS 1,071 4 97

• TSA: JB Pharma* has posted the highest growth for the month followed by La Renon and for MAT La Renon has posted highest growth followed by JB Pharma*
• SSA: JB Pharma* has posted highest growth for the month followed by FDC and for MAT JB Pharma* has posted highest growth followed by Ajanta

IQVIA TSA & SSA Dataset Dec'22 8

 Top Companies #31-40 Market Share Trend
0.72 Val Dec’22 MS Dec’22
0.70
(BLUE CROSS) 101 0.59%
0.68
(P&G HLTH) 98 0.57%
0.66
CORONA 93 0.54%
0.64
0.62 NOVARTIS* 88 0.52%
0.60 SYSTOPIC 83 0.48%
0.58 (HETERO*) 83 0.48%
0.56 (WIN MEDICARE) 77 0.45%
0.54 77 0.45%
MEDLEY
0.52
(H&H) 75 0.44%
0.50
FOURRTS 73 0.42%
0.48
0.46
0.44
0.42
0.40
0.38
Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22

• Corona & Fourrts have shown improvement in MS for Dec’22 as compared to Nov’22
• Novartis*, Systopic & Medley have maintained MS in the month of Dec’22
• Blue Cross, P&G, Hetero*, Win Medicare & H&H reflected dip in MS for Dec’22 as compared to Nov’22

IQVIA TSA & SSA Dataset Dec'22

9
 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

1
BLUE CROSS 101 9 97 P&G HLTH 88 90
21
P&G HLTH 98 3 92 LA RENON 88 107
26
CORONA 93 26 112 CORONA 78 112
8
NOVARTIS* 88 3 91 SYSTOPIC 74 96
5
Month

Month
SYSTOPIC 83 8 96 MEDLEY 71 93
4
HETERO* 83 12 99 NOVARTIS* 70 92
18
WIN MEDICARE 77 18 104 WIN MEDICARE 67 105
8
MEDLEY 77 6 94 HETERO* 66 96
4
H&H 75 7 95 H&H 64 92
11
FOURRTS 73 13 100 FOURRTS 62 99

BLUE CROSS 1,172 4 97 P&G HLTH 1,037 10 103

P&G HLTH 1,131 10 104 LA RENON 955 32 124
NOVARTIS* 1,049 3 97 MEDLEY 916 4 98
CORONA 1,030 17 110 SYSTOPIC 870 8 101
MAT

83 18 111

MAT
HETERO* 1,028 -12 CORONA 870
MEDLEY 977 4 97 HETERO* 831 -6 88
SYSTOPIC 971 8 101 NOVARTIS* 824 5 99
WIN MEDICARE 872 3 96 H&H 759 10 103
H&H 868 11 104 WIN MEDICARE 755 2 96
APEX 810 -2 92 APEX 718 -3 91

• TSA : Corona shows the highest growth for the month followed by Win Medicare while for MAT Corona has posted highest growth followed by H&H
• SSA: Corona shows the highest growth for the month followed by La Renon while for MAT La Renon has posted highest growth followed by Corona

IQVIA TSA & SSA Dataset Dec'22 10

 Top Companies #41-50 Market Share Trend
0.56
0.54
Val Dec’22 MS Dec’22
0.52
APEX 68 0.40%
0.50
BHARAT SERUM 67 0.39%
0.48
JANSSEN 66 0.38%
0.46
MEYER 66 0.38%
0.44
MSD* 64 0.38%
0.42
0.40
BOEHRINGER 61 0.36%
0.38 WALLACE 61 0.36%
0.36 DABUR 59 0.35%
0.34 (RAPTAKOS) 57 0.33%
0.32 CENTAUR 56 0.33%
0.30
0.28
0.26
0.24
Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22 Jul’22 Aug’22 Sep’22 Oct’22 Nov’22 Dec’22

• Apex, Bharat Serum, MSD*, Wallace & Dabur have shown improvement in MS for Dec’22 as compared to Nov’22
• Janssen, Meyer, Boehringer & Centaur have maintained MS in the month of Dec’22
• Raptakos reflected dip in MS for Dec’22 as compared to Nov’22

IQVIA TSA & SSA Dataset Dec'22 11

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

APEX 68 16 103
APEX 60 17 104
BHARAT SERUM 67 -1 88
MEYER 56 11 99
JANSSEN 66 8 96
WALLACE 55 10 98
MEYER 66 11 99
CENTAUR 52 6 94
Month

Month
MSD* 64 -2 87
BOEHRINGER 49 -9 81
BOEHRINGER 61 -5 84
RAPTAKOS 49 17 104
WALLACE 61 11 99
BHARAT SERUM 49 0 89
DABUR 59 6 94
DABUR 46 5 94
RAPTAKOS 57 21 107
JANSSEN 46 4 93
CENTAUR 56 8 96
MSD* 46 -9 81

BHARAT SERUM 802 -1 92 FOURRTS 687 6 99

JANSSEN 798 17 110 WALLACE 671 8 101
FOURRTS 792 6 99 MEYER 640 6 100
MEYER 751 7 100 BOEHRINGER 620 -4 90
MAT

MAT
MSD* 749 -20 75 RAPTAKOS 612 5 98
WALLACE 746 8 101 BHARAT SERUM 583 -5 89
BOEHRINGER 743 -3 91 JANSSEN 567 8 101
RAPTAKOS 693 6 100 MSD* 553 -23 72
ASTRA 584 16 109 CENTAUR 541 1 95
DABUR 583 -2 92 PHARMED 483 16 109

• TSA: Raptakos is the fastest growing company for the month followed by Apex and for MAT Janssen has posted highest growth followed by Astrazeneca

• SSA: Raptakos is the fastest growing company for the month followed by Apex, while for MAT Pharmed is the fastest growing company followed by Janssen

IQVIA TSA & SSA Dataset Dec'22 12

 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Dec'22 (in comparison to Nov’22), among the
Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• Torrent*, Zydus*, Pfizer, Alembic & Himalaya improved by 1 rank
each to reach 8th, 11h, 18th, 20th & 24th positions, respectively
In the month of Dec'22 (in comparison to Nov’22), among
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• Lupin, Torrent*, DRL*, USV, Alembic, JB Pharma & Eris*
improved by 1 rank each to reach 6th, 7th, 10th,15h, 18th, 22nd &
23rd positions, respectively

As per MAT Dec'22 (in comparison to Nov’22), among the Top As per MAT Dec'22 (in comparison to Nov’22), among the
25 companies Top 25 companies

• Sun* has maintained its top position in the IPM with a market • Sun* has maintained its top position in the IPM with a market
share of 8% share of 8%

• All companies maintained their ranks for MAT Dec’22 • All companies maintained their ranks for MAT Dec’22

IQVIA TSA & SSA Dataset Dec’22

13
 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

61 0.45 0.22
AUGMENTIN 78 DOLO 38 31
12 0.44 0.22
MIXTARD 76 TELMA 37 19
22 0.40 0.20
FORACORT 68 SHELCAL 35 17
Top 1-10

Top 21-30
16 0.39 0.20
GLYCOMET-GP 67 MOXIKIND-CV 34 49
44 0.32 0.19
CLAVAM 55 CALPOL 33 19
-6 0.29 0.19
LANTUS 50 ROSUVAS 32 24
23 0.29 0.19
THYRONORM 49 DEXORANGE 32 14
33 0.29 0.19
DUOLIN 49 ULTRACET 32 13
25 0.28 0.19
BETADINE 47 SEROFLO 32 14
44 0.28 0.18
BUDECORT 47 BETNOVATE-N 31 2
0.27 31 3 0.18
LIV-52 46 10 LEVIPIL
PAN 46 19 0.27 JANUMET 31 -16 0.18
0.25 0.18
Top 11-20

AZITHRAL 43 40 ECOSPRIN-AV 30 24

Top 31-40
MANFORCE 41 52 0.24 DUPHASTON 30 13 0.17
MONOCEF 40 17 0.23 CILACAR 30 18 0.17
PAN-D 39 25 0.23 MONTAIR-LC 30 18 0.17
NOVOMIX 39 4 0.23 ACILOC 29 20 0.17
UDILIV 39 17 0.23 ASTHALIN 29 20 0.17
ZERODOL-SP 39 27 0.23 VOLINI 29 -8 0.17
RYZODEG 38 34 0.22 PREVENAR-13 28 -18 0.17

• Augmentin is the topmost brand with 78 Crs of sales & MS of ~0.45% for the month

• Among top 40 brands, Augmentin has shown highest growth of 61% for the month followed by Manforce & Moxikind CV with a growth of 52% & 49%
respectively

IQVIA TSA & SSA Dataset Dec'22 14

 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Dec'22 Month (in comparison to Nov’22 Month)
• Augmentin gained 1 rank and is at No 1 position at month level with a growth of 61%
• Lantus,Thyronorm & Telma gained 1 rank each to secure 6th, 7th and 22nd position, respectively
• Amongst the top 10 Brands, highest growth is observed by Augmentin , Budecort & Clavam with a growth of 61% & 43% each
respectively
• Manforce,Ryzodeg & Shelcal gained 2 rank to secure 14th ,20th & 23rd position respectively with a growth of 52% ,34% & 17%
respectively.
• Novomix gained 3 ranks to secure 17th position with a growth of 4%
• Budecort & Moxikind-CV gained 4 ranks to secure 10th & 24th position with a growth of 44% & 49%
• Duolin, Pan-D & Zerodol-SP gained 5 ranks to secure 8th, 16th & 19th position with a growth of 33%, 25% & 27%

IQVIA TSA & SSA Dataset Jul’21

IQVIA TSA & SSA Dataset Dec’22 15
 Indian / MNC trends % Growth Over Same Month Last Year
25 23
Indian MNC
20
16 14
15
15
10 10 11 10
14
Month Growth

10 8 7 8
4 5 4
5 3
1 1
2 4
0
-6
-5 -8
-9
-10
JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22 JUL’22 AUG’22 SEP’22 OCT’22 NOV’22 DEC’22

Value (Rs. Crs)

Indian MNC

16,008 13,447 14,365 15,992 15,621 15,760 16,711 17,639 17,604 16,265 17,328 17,097
Share in IPM

13,231 11,022 11,731 13,141 12,842 12,975 13,836 14,590 14,624 13,467 14,338 14,148

2,777 2,424 2,634 2,852 2,779 2,785 2,874 3,050 2,980 2,798 2,991 2,950

JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22 JUL’22 AUG’22 SEP’22 OCT’22 NOV’22 DEC’22

• Indian companies has registered growth of 14% whereas MNC’s registered a growth of 8% for the month

IQVIA TSA & SSA Dataset Dec’22 16

 Acute / Chronic Trends ACUTE CHRONIC
30 27.0
25
20 15.4
13.8
15 12.9 13.7 10.1
12.5 11.2 12.9
12.6
9.4
Growth (%)

10 7.9 6.9 14.1

5.0 8.8 3.8
5 2.8 1.8 2.3
1.0 1.0
0
-5 -10.4
-10 -14.5
-15
JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22 JUL’22 AUG’22 SEP’22 OCT’22 NOV’22 DEC’22

Gwth %
23% 8% 42% 9% 12%
Top 5 TC 4s

307
271
Value (Rs 229 207
Crs) 167

COUGH PREP. ETHICALS GLIMEPIRIDE+METFORM. AMOXY. & CLAV. SOLIDS INTER.-ACTING+FAST ACTING FOOD SUPPLEMENTS

Value (Rs. Crs)

Top 3 Cos. in TC4

GLENMARK 45 USV 67 GSK* 56 ABBOTT* 153 APEX 29

DRL 44 LUPIN 28 ALKEM* 37 LUPIN 28 ALKEM 22

FRANCO 33 SUN* 27 MANKIND 32 CIPLA 9 SUN* 21

• Acute and chronic segments both have shown growth of 13% for the month

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Dec’22 17
 Top Therapy Trends
TSA

Value_DEC'22 (Rs. Crs) % Gwth SPLY Value_DEC'22 (Rs. Crs) % Gwth SPLY

C10A04 ROSUVASTATIN 109 13 J01C0G AMOXY. & CLAV. SOLIDS 229 42

C02C04 TELMISARTAN 99 15 J01C0H AMOXY. & CLAV. LIQUIDS 117 56

19 J01D0C CEFTRIAXONE INJECTABLS 105 20

Anti-Infectives
C02F06 AMLODIPINE+TELMISARTAN 85
C10A03 ATORVASTATIN 79 4 J01N01 MEROPENEM 101 13
Cardiac

C02G0H TELMISARTAN + HCT 68 5 J01F04 AZITHROMYCIN ORAL SOLIDS 100 28

C01E03 METOPROLOL 63 14 J01D0L CEFIXIME ORAL SOL. 74 17

C02F0Y SACUBITRIL + VALSARTAN 58 40 J01D0I CEFUROXIME ORAL SOLIDS 71 14

B01A0E ENOXAPARIN 56 -11 J01D0Z CEFTRIAXONE+SULBACTAM 66 18

C01D0B CILNIDIPINE 56 15 J01K05 PIPERACILLIN+TAZOBACTAM 66 16

C02F02 ATENOLOL+AMLODIPINE 55 7 J01D0V CEFPODOXIME SOLIDS 63 23

A02B0Q PANTOPR.+ DOMPERID. 124 13 A10B0Q GLIMEPIRIDE+METFORM. 271 8

A02B0R RABEPRA.+ DOMPERID. 96 6 A10C03 INTER.-ACTING+FAST ACTING 207 9
A02B0A PANTOPRAZOLE SOLIDS 94 13 A10B0B GLIMEPIRIDE+METFOR+VOGLIB 101 12
18

Anti Diabetic
A02B0S ESOMEPR.+ DOMPERID. 54 A10C05 LONG ACTING 89 4
A07K09 OTHERS 53 10 A10B0D METFORMIN + VILDAGLIPTIN 77 -1
GI

A02B01 RANITIDINE ORAL SOLIDS 52 20 A10C01 FAST ACTING 70 11

A06A0A LACTULOSE 50 28 A10B0W PIOGLITAZ.+METFORM.+GLIM. 62 6
A09A02 DIGEST. INC. ENZYME LIQUIDS 47 7 A10B07 METFORMIN + SITAGLIPTIN 58 -1
A06A07 MILK OF MAG AND COMB. 44 2 A10B0O METFORMIN + TENELIGLIPTIN 48 -13
A02A05 ANTACID+ANTIFLATU.LIQ 41 -3 A10B12 DAPAGLIFLOZIN 46 13

• In Cardiac, Sacubitril + Valsartan posted highest growth of 40%

• In AI, Amoxy. & Clav. Liquids has posted 56% growth which is highest amongst top therapy
• Pantopr.+ Domperid.is the top contributing subgroup in GI therapy value around 124 Cr with a growth of 13%
• In Anti diabetic, Dapagliflozin subgroup has posted highest growth of 13%

IQVIA
IQVIA TSA &TSA & SSA
SSA Dataset Dataset
Dec’22 Aug’21 18
 Top Therapy Trends
TSA

Value_DEC'22 (Rs. Crs) % Gwth SPLY Value_DEC'22 (Rs. Crs) % Gwth SPLY

V06E01 FOOD SUPPLEMENTS 167 12 R05B01 COUGH PREP. ETHICALS 307 23

A12A04 CALCIUM + COLECALCI. SOLI. 97 12 R03B01 LEVOCETIRIZ.+MONTELU SOLD 120 17

A11F02 MECOBALAMIN COMB. 91 4 R03C0R FORMOTERAL+BUDESONIDE 115 21

Respiratory
V06C01 INFANT FORMULAS 82 31 R05B05 LEVOSALBUTAMOL & COMB. 113 52
16
VMN

A11C02 PLAIN VIT.D 79 18 R05A02 COLD PREP. LIQUIDS 97

A11A04 OTH. MULTIVIT.-MIN. SOLIDS 72 7 R05B07 CHLORPHNMN+DEXTROMETHRPHN 67 36

A12A01 CALCIUM ORAL SOLIDS 45 13 R03C02 BUDESONIDE 58 45

A15A01 APPETITE STIMULANTS 40 -4 R03C0S IPRATROPIUM + LEVOSALBU. 58 31

V06E05 ADULT WELLNESS 39 11 R05B03 CODEINE AND COMB. 56 -13

A11F05 MECOBALAM.+COLECALI. COMB 35 17 R05A01 COLD PREP. SOLIDS 54 5

M02A01 NSAIDS 82 2 D02A01 EMOLLIENTS,PROTECTIVES 141 13

N02B05 PARACETAMOL ORAL SOLIDS 73 18 D01C03 ITRACONAZOLE 76 1
M05C02 CALCITRIOL COMB. 72 6 D11A09 OTH.DERMATOLOGICAL PREP. 56 15
M01A0G PARACE.+ACECLOF.+SERRAPE. 65 24 D06A08 MUPIROCIN 37 25

Derma
M01A0U ACECLOFENAC + PARACETAMOL 49 11 D01A02 LULICONAZOLE 33 -6
Pain

N02B06 PARACETAMOL ORAL LIQUIDS 45 37 D07D0C CLOBET+MICONAZOL+NEOMYCIN 32 3

N02B0K PARACETAMOL + TRAMADOL 43 10 D02B01 SUNSCREENS 31 29
M05B0C COLLAGEN COMB 42 23 D16A0D OTH HAIR CARE PREPS. 31 11
N02B07 PARACETAMOL INJECTIONS 40 35 D07B0A BETAMETH.+NEOM. 31 2
M02A02 OTH. ANTIRHEU. NON-STR. 35 10 D02C07 HYDROQU.+TRETI.+MOMETA. 31 13

• In VMN therapy, food supplements is the top contributing subgroup with 167 Cr of sales posted growth of 12%
• In Respiratory market, cough prep is observed to be top contributing one with 307 Cr of sales posted growth of 23%
• In Pain market, paracetamol oral solids, liquids & inj contributed ~ 158 Crs of sales with 18%,37% & 35% growth, respectively
• Emollients protectives registered highest sales of 141 Cr in derma market with 13% growth while the highest growth of 29% is observed in Sunscreens

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Dec’22 19
Top Therapy Trends
TSA

Value_DEC'22 (Rs. Crs) Value_DEC'22 (Rs. Crs) % Gwth SPLY

% Gwth SPLY
10 B03A01 CONV.IRON SOLIDS 108 7
N03A0T LEVETIRACETAM 86
7 G03D04 DYDROGESTERONE 85 57
N06C02 ESCITALOPRAM+CLONAZEPAM 41
21 B03A02 CONV.IRON LIQUID 84 13
N03A0V GABAPENTIN + NORTRIPTYLIN 35
7 71 3
Neuro / CNS

G03D03 PROGESTERONE

Gynaec.
N07C01 BETAHISTINE 35
6 B03A03 CONV.IRON INJ. 51 5
N03A04 SODIUM VALPROATE ORAL SOLIDS 27
5 G03K02 MIFEPRISTONE+MISOPROSTOL 40 25
N03A0J OXCARBAZEPINE 26
13 G02C01 OTHER GYNAECO.PREP. 31 3
N07A01 PREGABALIN 25
7 G03G06 HUMAN MENOPAUSAL GONADOTROP. 30 15
N07A02 PREGABALIN+MECOBALAMIN 25
15 G03G05 HUMAN CHORIONIC GONADOTROP. 29 22
N03A0I NORTRIPTYLINE+PREGABALIN 24
12 G03D02 NORETHISTERONE 23 12
N06B03 CITICOLINE + PIRACETAM 21

• In Neuro therapy, levetiracetam is the top valued subgroup with 86 Crs of sales and 10% of growth
• In Gynaec therapy, conv iron solids, liquids and inj. together have contributed ~243 Cr of sales to the entire therapy
• Among the top gynae Therapies, Dydrogesterone has posted highest growth of 57%

IQVIA
IQVIA TSATSA
& SSA&Dataset
SSADec’22
Dataset Aug’21 20
 Key changes
PTR Changes (Top 50 brands) New Introduction

➢ 891 new packs were Introduced in Dec’22

➢ Total number of SKUs with PTR changes in Dec’22 is 2720.
➢ Among the top 50 brands of the industry, PTR changes reflected in SKUs
of the following brands : Calpol, Liv-52, Betadine, Zerodol-Sp, Moxikind-Cv,
Levipil, Gemer, Liv-52, Liv-52, Seroflo, Foracort, Taxim-O, Monocef,
Mikacin, Pantop

New Lab & Corporate Brand Transfer

➢ 38 Corporates & Labs were introduced in Dec’22 dataset ➢ No brand transfer in Dec’22

IQVIA TSA & SSA Dataset Dec’22

21
THANK YOU